Preferred Label : Resiquimod Hydrogel-based Sustained-release formulation;
NCIt synonyms : TransCon TLR7/8 Agonist; Intratumoral Release TLR7/8 Agonist; Localized Release TLR7/8 Agonist;
NCIt definition : A hydrogel carrier-based, sustained intra-tumoral release formulation of resiquimod,
a Toll-like receptor (TLR) 7/8 agonist and an imidazoquinolinamine, with potential
immunostimulating and antineoplastic activities. Upon intra-tumoral administration,
resiquimod binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages,
and B-lymphocytes, and activates the TLR signaling pathway, which results in the induction
of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB)
and activation of other transcription factors. Subsequently, NF-kB-dependent gene
expression is induced and cytokine production increases, especially interferon-alpha
(INF-a), which results in the enhancement of T-helper 1 (Th1) immune responses. Activation
of DCs also results in the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte
immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR
family, play fundamental roles in the activation of the immune system.;
NCI Metathesaurus CUI : CL1662471;
Origin ID : C179719;
UMLS CUI : C5555874;
Semantic type(s)
- concept_is_in_subset
- has_target
